DelMar presents positive preclinical data on VAL-083 for treatment of non-small cell lung cancer
20 April 2015 | By Victoria White
DelMar Pharmaceuticals presented positive preclinical data on its lead product candidate VAL-083 for treatment of platinum drug-resistant NSCLC at AACR2015...